|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
NOTE: If you attended this live CE activity that was held on October 1, 2019 at the SIDP Annual Meeting AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-19-477-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.
This activity will discuss several new antimicrobial agents active against resistant Gram-negative pathogens approved in recent years. By examining gram-negative mechanisms of resistance and their prevalence, clinicians will have a better understanding of unique spectrum coverage and specific deficiencies of new agents. Several clinical trials will be reviewed as they relate to treatment against specific infection types and the likelihood of resistance.
This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.
The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:
- Examine gram-negative mechanisms of resistance their prevalence.
- Analyze likelihood of antimicrobial activity based on mechanism of resistance.
- Compare and contrast antimicrobial agents for gram-negative infections.
Betsy Hirsch, PharmD
Department of Experimental and Clinical Pharmacology
University of Minnesota College of Pharmacy
Release Date: 10-1-2019
Expiration Date: 10-1-2022
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-477-H01-P has been assigned to this home-study knowledge-based activity (initial release date 10-1-2019). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. Hirsch has received research funding from Merck and advisory board honoraria from Paratek Pharmaceuticals and Nabriva Therapeutics.
This activity is supported by an educational grant from Shionogi.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
|Activity Number||Credit Amount||Accreditation Period|
|0221-9999-19-477-H01-P||1 Contact Hour||October 01, 2019 - October 01, 2022|